Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Systems biology and "omics" (1)
- Cardiovascular continuum
- Proteomics (1)
- Proteomics (2)
- Publications on proteomics
- Rationale for proteomic studies
- Samples
- Platforms
- LC-MS/MS platform
- Technical challenges
- Post translational modifications
- Unravelling pathophysiology (1)
- Epicardial fat
- Unravelling pathophysiology (2)
- Western blot and IHC
- NBT assay of ROS
- Biomarker of disease
- Urinary proteomics (CE/MS platform)
- Why urine?
- CE/MS platform
- Methods (1)
- Methods (2)
- Patients
- 239 biomarker panel
- Identification of proteins
- Single marker
- Two markers
- Three markers
- Better discrimination with more markers
- Effect of drug therapy
- Pre-eclampsia (1)
- Pre-eclampsia (2)
- Normal pregnancy
- Maternal risk factors
- Study design
- Clinical characteristics
- Pregnancy specific proteomic biomarkers
- Pre-eclampsia specific biomarkers (1)
- Pre-eclampsia specific biomarkers (2)
- Change in classification factor
- Sequencing
- Plasma proteome
- Pre-eclampsia and cardiovascular risk
- Serum proteomics (1)
- Serum proteomics (2)
- Urinary proteomics (SELDI) (1)
- Urinary proteomics (SELDI) (2)
- Organ damage
- Stroke (1)
- Stroke (2)
- Heart failure
- Biomarker of risk
- Chronic kidney disease pattern
- Diabetic nephropathy (1)
- Diabetic nephropathy (2)
- Study flow chart
- Integrating "omics" data
- Systems biology and "omics" (2)
- Summary and conclusions
- Acknowledgements
Topics Covered
- Systems biology
- Definition of proteomics
- Proteomics: rationale and practical aspects
- Proteomics in cardiovascular pathophysiology
- Proteomics to detect biomarkers of cardiovascular disease
- Urinary proteomics using capillary electrophoresis / mass spectrometry
- Proteomics of coronary artery disease
- Proteomics of pre-eclampsia
- Proteomics of other cardiovascular diseases: stroke, heart failure, diabetic nephropathy
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Delles, C. (2013, November 5). Proteomics in cardiovascular disease: clinical considerations [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/TGUN8661.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Christian Delles has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Proteomics in cardiovascular disease: clinical considerations
Published on November 5, 2013
34 min